To learn about our parent company, Takeda Pharmaceutical Company Limited, please visit http://www.takeda.com/
Please contact us at US.email@example.com or (224) 554-5499.
The Children’s National Hospital Rare Disease Institute and Takeda Partner to Standardize Care for Patients With Rare Diseases
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
TAKEDA FURTHER ENABLES HEMOPHILIA A PERSONALIZED CARE WITH LAUNCH OF MYPKFIT® SOFTWARE FOR ADYNOVATE ® [ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED]
Takeda to Highlight Research Commitment in Bleeding Disorders and Personalized Care at American Society of Hematology (ASH) Virtual Annual Meeting
Takeda to Present Rare Bleeding Disorders Research at Thrombosis & Hemostasis Summit of North America (THSNA) 2020
SEE ALL NEWS AND RELEASES >
Copyright 2021 Takeda Pharmaceutical Company Limited. All rights reserved.Certified Top Employer
You are about to leave www.Takeda.com/en-us and be redirected to another Takeda domain.